Acalabrutinib is a selective Bruton’s tyrosine kinase (BTK) inhibitor used to treat mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). It is indicated for patients who have received at least one prior therapy for their malignancy. By inhibiting BTK, Acalabrutinib disrupts signaling pathways crucial for the survival and proliferation of malignant B-cells, thereby slowing cancer progression. This targeted therapy is essential for managing specific hematological cancers, offering a more effective treatment option with potentially fewer side effects compared to traditional chemotherapy. In summary, Acalabrutinib is vital for treating certain types of blood cancers.
Acalabrutinib selectively binds to and irreversibly inhibits BTK, blocking downstream signaling pathways that promote the survival and proliferation of malignant B-cells.
No published brands for this salt yet.